Latest current cash for KYTX: $32M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), KYTX shows a current cash of $32M. That compares with $57M in the prior-year period — down 43.4% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, KYTX's current cash is now $32M (was $57M) — a 43.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Kyverna Therapeutics is outperforming or lagging.
Tracking KYTX's current cash over time shows whether Kyverna Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $32M That compares with $57M in the prior-year period — down 43.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has Kyverna Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $32M) with ownership activity and broader fundamentals.